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Depressive and Anxiety Symptoms Predict Sustained Quality
of Life Deficits in HIV-Positive Ugandan Adults Despite
Antiretroviral Therapy
A Prospective Cohort Study
Amara E Ezeamama, PhD, Makhabele N Woolfork, MPH, David Guwatudde, PhD, Danstan Bagenda,
PhD, Yukari C Manabe, MD, Wafaie W Fawzi, MD, DrPH, and Mary C Smith Fawzi, ScD
Abstract: The impact of psychosocial status at onset of antiretroviral
therapy on changes in quality of life (QOL) and subjectively rated health
(SRH) among adults on ART in resource-limited settings is poorly
understood. Therefore, we evaluate the association between stigma,
anxiety, depression, and social support and change in QOL and SRH in
HIV-infected Ugandan adults during an 18-month period.
Psychosocial indicators were assessed at enrollment using structured
questionnaires. QOL and SRH measures were assessed at months 0, 6, 12,
and 18 using the Medical Outcomes Survey-HIV. Linear mixed models
determined risk estimated differences in QOL and SRH in relation to
quartiles of each psychosocial status indicator. Repeated measures gener-
alized estimating equations modeling was implemented to assess differ-
ences in likelihoodof improvedversus nonimprovedSRHduring follow-up.
QOL scores and SRH improved significantly for all participants over 18
months (P< 0.0001). The gain in QOL increased dose-dependently as
baseline depressive symptoms (time
depression P< 0.001) and
anxiety levels (timeanxiety P< 0.001) declined. Lower social
support was associated with worse QOL at baseline (P¼ 0.0005)
but QOL improvement during follow-up was not dependent on
baseline level of social support (timesocial support P¼ 0.8943)
or number of stigmatizing experiences (timestigma P¼ 0.8662).
Psychosocial determinants did not predict changes in SRH in this
study.
High levels of depression and anxiety symptoms at HAART initiation
predicts lower gains in QOL for HIV-positive patients for as long as 18
months. Long-term QOL improvements in HIV-infected adults may be
enhanced by implementation of psychosocial interventions to reduce
depression and anxiety in HIV-infected adults.
(Medicine 95(9):e2525)
Abbreviations: BMI = body mass index, HAART = highly active
antiretroviral therapy, PLH = people living with HIV, QOL =
quality of life, SRH = self-rated health, SSA = Sub-Saharan Africa.
INTRODUCTION
A n estimated 25 million people were living with humanimmunodeficiency virus (HIV) in Sub-Saharan Africa
(SSA) in 2013 contributing to over 70% of the HIV burden
worldwide.1 The expansion of access to highly active antire-
troviral therapy (HAART) among HIV-infected persons in
resource-limited settings has been a key factor in prolonging
life. HAART has been delivered to 65% of people who are
eligible2 and has added over 9 million life-years in SSA.3
Uganda, a country in the region with a generalized HIV epi-
demic, has an estimated prevalence of 7.3% with the burden
shifting from 30 to 34 year-olds to persons 35 years of age and
older.4 Thus, as patients age with chronic HIV, survival at high
levels of functioning has become of central importance in the
clinical management of HIV.
Patients with chronic HIV navigate a host of physical
(pain, energy, and vulnerability to infection), social (connec-
tions with friends or family and stigma), and emotional factors
(problem-solving, concentration, and stress) that impact daily
life. In the long-term, maintenance of optimal physical, social,
and emotional health outcomes in this population may require
reliance on psycho-spiritual strength or resiliency for coping,
robust social support from friends, family and providers, com-
passionate care at the interface of health care delivery, and
positive-reframing for self-management.5 High rates of psy-
chosocial attributes such as anxiety, depression, and stigma are
reported by HIV-infected patients regardless of race, sex, or
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sexual orientation and may affect long-term functional capacity
in these populations.6
Among Brazilian people living with HIV (PLH), ease of
performing activities of daily living, higher treatment adher-
ence, physical activity, ability to self-care, and adequate social
interaction have been associated with improved self-rated
health (SRH) whereas intense feelings of worry and anxiety
were associated with worse SRH.7 Similarly, higher levels of
social support were associated with increased overall quality of
life (QOL) in American men with HIV8 while depressive
symptoms predicted worse role and emotional functioning
scores, and general health outcomes overtime.8,9 The paucity
of data on psychosocial determinants of QOL improvement in
adults with chronic HIV in SSA has been recognized.6 More-
over, an analysis of long-term changes in QOL and SRH in
patients on HAART in resource-limited settings is warranted.
As access to HAART continues to expand in SSA, this infor-
mation will be useful in identifying modifiable social barriers
that may drive the persistence of health disparity among HIV-
infected adults linked to clinical care. This study is designed to
assess the impact of psychosocial determinants measured at
enrollment (social support, anxiety, depression, and stigma) on
change in QOL and SRH over 18 months among PLH receiving
HAART in urban Uganda. We hypothesize that patients with
high levels of social support and low levels of anxiety, depres-
sion, and stigma will realize greater improvements in SRH and
QOL over 18 months on HAART.
METHODS
Study Population and Design
Data were analyzed from the Trial of Vitamins study, a
randomized, double-blind, placebo-controlled trial designed to
assess whether one recommended dietary allowance dose of
multivitamin supplements (vitamins B-complex, C, and E)
would improve immune function, weight gain, and overall
QOL in PLH at least 18 years of age in Kampala, Uganda.
Eligible subjects had to meet the following criteria: HIV-
positive status, aged 18 years or more, initiating antiretroviral
therapy during randomization or having been on HAART for 6
months or less, no intention of migrating or relocating more than
20 km outside of the Infectious Disease Institute HIV care clinic
during the next 18 months, agree to allow home and follow-up
visits, and provide written informed consent. Trial of Vitamins
study design is presented in detail elsewhere.10
Measures
Primary Determinants
Four psychosocial factors were measured at baseline:
(1) Cumulative stigma was defined as the patient’s total score
in response to questions on the following experiences since
HIV diagnosis, with responses coded as reported ‘‘yes’’
(score¼ 1) versus ‘‘no’’ (score¼ 0): teased, insulted, or
sworn at; loss of respect/standing with family/community;
property loss; spousal abandonment; loss of customers or
job; family abandonment/forced banishment to village/
rural area; exclusion from social gatherings; and children
taken away. For analytic purposes, the sum of stigmatizing
experiences was categorized as 0, 1, and 2 or more.
(2) Depressive symptoms were defined as the patient’s total
score to the following: lack of energy; loss of sexual
interest/pleasure; loss of appetite; future hopelessness;
feelings of loneliness; excessive worry; feeling that
everything is an effort; and feelings of worthlessness.
For each depression and anxiety symptom, severity was
graded as: not at all (score¼ 0), a little (score¼ 1), quite a
bit (score¼ 2), and extremely (score¼ 3). Anxiety level
was defined by patient report of the following feelings:
scared suddenly without reason; faintness, dizziness or
weakness; nervousness or shakiness inside; trembling;
tension; or restlessness. For each depression and anxiety
symptom, severity was graded as: not at all (score¼ 0), a
little (score¼ 1), quite a bit (score¼ 2), and extremely
(score¼ 3).10 Social support was defined as receipt of the
following: visits from friends and family; advice about
important things in life; ability to talk to trusted person
about personal/work problems; help with money during
emergencies; and assistance when sick and love/affection.
For social support components, patients rated support
adequacy as: never (score¼ 0), much less than I would like
(score¼ 1), less than I would like (score¼ 2), and as much
as I would like (score¼ 3).10
Confounders: Clinical, Socio-Demographic, and
Behavioral Characteristics
To determine CD4-cell count, an FACS Calibur flow
cytometer (Becton-Dickinson, San Jose, CA) was used to
measure absolute T-cell lymphocyte CD4 counts in cells/micro-
liter. Body mass index (BMI) was calculated as the ratio of
weight and the height squared for each participant. BMI values
were used to define underweight (BMI< 18.5), normal weight
(18.5BMI< 25), overweight (25BMI< 30), and obese
(BMI>¼ 30).11
Age was measured in years and categorized as: 25, 26–
35, 36–45, and 46þ years. Socioeconomic status was measured
by years of education analyzed in 2 categories: above elemen-
tary versuselementary educational level. Independent income
source was included as an additional binary measure of SES
based on response to the question ‘‘do you have your own
income?’’ Employment status was defined by self-identifi-
cation as unemployed, unskilled laborer, engagement in infor-
mal income generating activity (e.g., roadside vendor who sells
inexpensive handicrafts or food items), driver/skilled laborer,
and professional occupations (includes office worker, police,
professional, bus owner).
Marital status was coded as: single/never married (refer-
ence for all analyses), married monogamously, married poly-
gamously, cohabiting, divorced/separated, or widowed.
Biological sex was defined as male or female with males the
reference category in all analyses. History and current use of
alcohol and cigarette smoking were self-reported by patients.
For analytic purposes current versus no use of alcohol and ever
versus never smoking status were the categories used.
Outcome Variables
Two health indicators (QOL and SRH) were measured at
baseline as well as 3, 12, and 18 months of follow-up.
1. SRH:We defined SRH in line with extant literature12,13
by patients rating their overall health on a 5-point ordinal scale
as excellent (score¼ 5), very good (score¼ 4), good
(score¼ 3), fair (score¼ 2), or poor (score¼ 1) relative
to an adult of same age and sex in their community.
SRH was analyzed as a dichotomous outcome with low con-
sisting of poor/fair and high including good/very good/
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excellent, to accommodate the distribution of SRH rankings in
our sample.
2. QOL: QOL was assessed with the Medical Outcomes
Study HIV Health Survey (MOS-HIV) translated and culturally
adapted for the study area.14,15 It includes 10 subscales: per-
ceived health (5 items), pain (2 items), overall QOL (1 item),
health transition (1 item), role functioning (2 items), social
functioning (1 item), physical functioning (6 items), cognitive
functioning (4 items), health distress (3 items), and energy (4
items). Variables were coded such that higher scores corre-
sponded to better QOL. Within each subscale, a score was
calculated as the sum of patient responses to individual ques-
tions. An overall QOL score included the sum of all subscale
scores. We linearly transformed the overall score so that the
highest score would be 100.
Statistical Analysis
The summed composite of depressive symptoms, anxiety,
and social support were categorized based quartiles of respect-
ive score distribution in the sample. The 3 lower quartiles were
each compared to the 4th quartile. QOL was analyzed as a linear
outcome variable while SRH was evaluated as a
dichotomous endpoint.
First, descriptive analyses were implemented to describe
the socio-demographic, clinical, and behavioral characteristics
of the study sample at enrollment by high versus low QOL and
SRH. We estimated differences in the relative proportion or
means of respective covariates using Chi-square or t-tests,
respectively. All variables associated with respective outcomes
at P of less than 0.2 were considered candidate confounders and
further evaluated in multivariable analyses.
Secondly, we determined the bi-annual temporal trend in
QOL and SRH scores from enrollment through month 18 of
follow-up. Then we implemented 2 primary sets of analyses to
determine whether the rate of change in QOL and high versus
low SRH ratings varied by baseline psychosocial factors. To
determine psychosocial status-related differences in QOL, we
implemented linear repeated measures analyses using the SAS
Proc Mixed procedure. We calculated baseline psychosocial
status related differences in rate of QOL increase and corre-
sponding 95% confidence intervals. We assumed an unstruc-
tured covariance matrix to address repeated QOL assessment
within study participants. To assess differences in likelihood of
improved versus nonimproved SRH during follow-up, we
implemented repeated measures generalized estimating
equations modeling. We assumed a binomial distribution for
the dichotomous response and specified a logit link. From this
model, the odds of high versus low SRH were determined in
relation to baseline psychosocial predictors. Multivariable
models adjusted for an extensive array of socio-demographic,
behavioral, and clinical characteristics if warranted based on
bivariate analyses (i.e., if P< 0.2). All analyses were per-
formed with SAS software, version 9.4 (SAS Institute, Cary,
NC).
Ethical Approval
The parent study was approved by the Scientific Review
Committee of the Infectious Diseases Institute at Makerere
University College of Health Sciences; and the Institutional
Review Boards of Harvard School of Public Health and that of
Makerere University School of Public Health. The study was
registered by the Uganda National Council for Science and
Technology (UNCST).
RESULTS
Baseline Characteristics
All 400 participants enrolled in the parent trial were
included in this analysis. Participants were predominantly
female (69.2%), aged 30 to 39 (45.2%), divorced or separated
(30.8%), had their own income (74%), had an informally
generating income (32%), and less than an elementary edu-
cation (41%). History of cigarette smoke, current alcohol con-
sumption, and multivitamin use were all low (17.5%, 20.2%,
and 22%) at trial enrollment. Fifty percent (n¼ 200) were
HAART naive. The average BMI and CD4 count at enrollment
were 23.8 (SD¼ 4.4) kg/m2, and 148.9 (SD¼ 95.9) cells/mL,
respectively. Over half of the sample experienced low QOL
(52.3%) and poor/fair SRH (54.5%) at baseline (Tables 1 and 2).
QOL and SRH Trends Overtime
The number of participants present at months 0, 6, 12, and
18 were 400, 380, 369, and 366, respectively, reflecting a 91.5%
rate by study end. The greatest improvement occurred between
baseline and 6 months for mean QOL scores (6.2 points) and
high-SRH (29% difference). After 6 months, mean QOL and
percent classified as high SRH was sustained over 18 months.
Effect of Baseline Psychosocial Status on QOL
Table 3 shows the difference in the rate of patients’ QOL
overtime within each psychosocial determinant level for those
with lesser amounts of stigma compared to 2 or more events and
the 3 lower quartiles for depression, anxiety, and social support
compared to the highest amount. Adjusted models controlled for
age, sex, presence of own income, education, and current
alcohol use. The change in the rate of QOL declined dose-
dependently and significantly as stigmatizing events increased
(P-value¼ 0.0150). At all follow-up periods, low stigma was
associated with QOL advantage with significant differences
evident for patients reporting none versus 2 or more stigmatiz-
ing events at 12 (QOL difference¼ 4.3, 95% CI: 0.7–7.9) and
18 (QOL difference¼ 4.1, 95% CI: 1.1–7.5) months. Similarly,
improvement in QOL declined dose-dependently and signifi-
cantly at each follow-up period as depression and anxiety
worsened (timegroup P< 0.0001). Overall, the disadvantage
of lower QOL for patients with high depression and high anxiety
at HAART onset was observed at 18 months of follow-up.
Finally, patients reporting lower social support had dose-depen-
dently and significantly worse QOL at baseline (P¼ 0.0005).
However, individuals reporting lower levels of social support
had lower QOL scores on average at all follow-up intervals. By
month 18, the QOL scores were significantly lower for patients
in the least (QOL difference¼3.9, 95% CI: 6.5, 1.3) and
2nd lowest quartile (QOL difference¼3.0, 95% CI: 5.5,
0.5) of social support compared to the highest quartile.
Finally, the rate of QOL improvement during follow-up did
not differ significantly by baseline level of social support
(timegroup P¼ 0.8943) and stigma (P¼ 0.8662).
Effect of Baseline Psychosocial Status on SRH
The likelihood of high SRH at baseline and overtime in
relationship to baseline psychosocial determinants is shown in
Figure 1. The odds of a high versus low SRH at baseline
increased dose-dependently for participants in the lower quar-
tiles of depressive symptoms (P< 0.0001) and lower quartiles
of anxiety (P¼ 0.002). By study end, the difference in odds of
high SRH was significantly higher for patients in the lowest
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versus highest quartile of anxiety (OR¼ 3.5, 95% CI: 1.5, 8.1),
and the 2 lowest versus highest quartiles of depressive symp-
toms (Q1 vs Q4: OR¼ 5.0, 95% CI: 2.0, 12.4). Similarly, as
baseline quartiles of social support decreased, the odds of a high
versus low reported health status declined dose-dependently
and significantly (P¼ 0.0037). By study end, however, partici-
pants in the 2 lowest versus highest quartile of SRH (Q1 vs Q4,
OR¼ 0.23, 95% CI: 0.08, 0.63) were at significantly lower odds
rating their health as high compared to participants reporting the
highest level of social support at enrollment. Overall, associ-
ations between psychosocial variables and high versus low SRH
were not significant overtime (Table 4).
DISCUSSION
We demonstrate that the average QOL score at enrollment
increased with social support score but declined with increas-
ing number of reported stigmatizing events, depressive symp-
toms, and anxiety level. Patients reporting lower social support
levels at enrollment were less likely to subjectively rate their
health as high. Conversely participants with the lower levels of
depressive symptoms and anxiety at enrollment were more
likely to highly rate their health and had higher QOL scores.
These observations are in support of similar cross-sectional
reports among HIV-infected adults from India and Ethio-
pia.16,17 The depression-related differences inQOLwe observe
TABLE 1. Socio-Demographic Characteristics of Participants, by QOL at Baseline
Variables
Overall 400
(100%) N, %
Low QOL 209
(52.3%) N, %
High QOL 191
(47.7%) N, % P-Value
Female sex 277 (69.2) 151 (37.7) 126 (31.5) 0.1740
Age categories, years 0.1302
<20 6 (1.5) 3 (1.4) 3 (1.6)
20–24 29 (9.7) 25 (12.0) 14 (7.3)
25–29 53 (13.2) 32 (15.3) 21 (11.0)
30–34 80 (20.0) 37 (17.7) 43 (22.5)
35–39 101 (25.2) 52 (24.9) 49 (25.7)
40–44 54 (13.5) 27 (12.9) 27 (14.1)
45–49 39 (9.8) 19 (9.1) 20 (10.5)
50–54 17 (4.3) 5 (2.4) 12 (6.3)
55þ 11 (2.8) 9 (4.3) 2 (1.0)
Marital status
Single never married 41 (10.3) 24 (11.5) 17 (8.9) 0.5195
Married monogamously 103 (25.8) 56 (26.8) 47 (24.6)
Married polygamously 32 (8.0) 13 (6.2) 19 (9.9)
Cohabiting 34 (8.5) 21 (10.0) 13 (6.8)
Divorced/separated 123 (30.8) 61 (29.2) 62 (32.5)
Widowed 67 (16.8) 34 (16.3) 33 (17.3)
Objective socioeconomic status indicators
Presence of own income 296 (74.0) 139 (66.5) 157 (82.2) 0.0004
Educational level
<Elementary 164 (41.1) 85 (40.9) 79 (41.4) 0.1229
Elementary 54 (13.5) 28 (13.5) 26 (13.6)
Some O’Level 80 (20.0) 50 (24.0) 30 (15.7)
O’Level graduate and higher 101 (25.3) 45 (21.6) 56 (29.3)
Employment/occupational status
No income 52 (13.0) 36 (17.2) 16 (8.4) 0.0590
Unskilled labor 105 (26.2) 54 (25.8) 51 (26.7)
Informal income generating activity 128 (32.0) 65 (31.1) 63 (33.0)
Driver/skilled laborer 52 (13.0) 21 (10.1) 31 (16.2)
Professional 63 (15.8) 33 (15.8) 30 (15.7)
Behavioral factors
Ever smoked 70 (17.5) 35 (16.8) 35 (18.3) 0.6782
Current alcohol use 81 (20.25) 35 (16.8) 46 (24.1) 0.0682
Multivitamin use history 88 (22.0) 48 (23.0) 40 (21.0) 0.6255
HAART duration
0 months 200 (50.0) 109 (52.2) 91 (47.6) 0.3676
<¼6 months 200 (50.0) 100 (47.8) 100 (52.4)
Mean (SD) Mean (SD) Mean (SD)
BMI, kg/m2 23.8 (4.40) 23.1 (3.77) 24.5 (4.85) 0.0009
CD4 cell count, cells/mL 148.9 (95.9) 139.6 (94.7) 159.1 (96.4) 0.0424
BMI¼ body mass index, HAART¼ highly active antiretroviral therapy, QOL¼ quality of life.
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at enrolment is consistent with a previous report among Ugan-
dan PLH.18
As expected, we found that QOL scores and participant
subjective rating of their health increased during follow-up with
highest increases observed by the 6th month and maintained
over the remaining 12 months of follow-up. This observation is
in line with specific investigations among HIV-infected patients
from South Africa and Uganda.18–20 Over 18 months of follow-
up, patients that reported lower levels of depression and anxiety
at HAART initiation experienced dose-dependently greater
QOL improvement compared to the most depressed and the
most anxious participants. Low levels of social support and the
number of stigmatizing experiences were associated with lower
QOL scores and lower likelihood of high SRH in some follow-
up intervals – particularly when the extremes of respective
psychosocial measures are compared. However, the overall
trend in the change of QOL and SRH during follow-up did
not differ significantly by reported stigma and social support
level at participant enrollment.
We demonstrate sustained dose-dependent QOL disadvan-
tage over 18 months of follow-up for patients who began
HAART with high levels of depression and anxiety or have
high levels of depression and anxiety within 6 months of
HAART initiation. Our finding of the inverse association
between patient anxiety, depression symptoms, and QOL gain
is in line with observations in HIV-infected US populations.21
Our findings also correspond with 1 longitudinal study with 12
months follow-up implemented in rural Uganda among HIV-
infected adults with WHO disease stages between 1 and 4 all
HAART naive at enrolment.18 We replicate the depression-
dependent difference in QOL and confirm that the magnitude of
disadvantage may decline with time; however, we also show
that the QOL disadvantage associated with high depressive
symptoms at HAART initiation does not disappear altogether
but persists for as long as 18 months.18 We highlight important
differences in samples between these studies. Ours included an
urban sample of patients with World Health Organization stage
3 disease while Stangl et al18 enrolled rural HIV patients of all
WHO disease stages. Advanced HIV disease stage is known to
be associated with depression and lower QOL.20 Hence, our
sample could be especially vulnerable to depression related
reduced QOL during HAART. In addition, some differences in
the prevalence of stigma, social support, and their associated
relationships with QOL may exist between our urban sample
and the rural sample of adults investigated by Stangl et al.22
Long-term prospective studies in both urban and rural settings
with repeated assessment of psychosocial status indicators will
clarify how psychosocial status evolves during HAART and its
impact on patient wellbeing. This information will be of utility
for devising targeted interventions to enhance QOL in PLWHA.
In this same sample, we previously demonstrated that CD4 cell
count increased overtime as patients benefitted from HAART.
However, differences in immune recovery persisted for those
vitamin D deficient compared to those sufficient at enroll-
ment.23 The present study suggests that in addition to HAART,
a multidisciplinary clinical management approach including
interventions to reduce micronutrient deficiencies, anxiety,
and depression may be important complimentary therapies
for holistic management of patients living with chronic
HIV infection.
Of note, we find no evidence that the overall trend in
likelihood of patients reporting high versus low SRH was
dependent on baseline psychosocial measures. The incongru-
ence of associations between psychosocial determinants and
QOL and SRH as outcomes was not expected. This divergence
could in part be explained by the greater robustness of QOL (a
composite measure including several questions) versus SRH
which is assessed by a single question as measures of well-
being.10,24 Similarly, we were surprized that baseline stigma did
not predict the overall trend in rate of change in QOL or SRH
during follow-up given the described negative impact of stigma
in populations with chronic HIV-infection6,25,26 and its reported
TABLE 2. Baseline Sample Description According to Psychosocial Status Indicators – Overall and Within Strata of High Versus Low
Quality of Life (QOL)
Overall 400
(100%) N, %
Low QOL 209
(52.3%) N, %
High QOL 191
(47.7%) N, % P-Value
No. of serious stigma experienced within 12 months
0 283 (70.8) 143 (68.4) 140 (73.3) 0.4337
1 69 (17.3) 37 (17.7) 32 (16.8)
2þ 48 (12.0) 29 (13.9) 19 (9.9)
Total depression symptom score quartiles
1 (Lowest) 105 (26.3) 26 (12.4) 79 (41.4) <0.0001
2 125 (31.3) 58 (27.8) 67 (35.1)
3 88 (22.0) 58 (27.7) 30 (15.7)
4 (Highest) 82 (20.5) 67 (32.1) 15 (7.8)
Total anxiety symptom score quartiles
1 (Lowest) 121 (30.3) 33 (15.8) 88 (46.0) <0.0001
2 95 (23.8) 49 (23.4) 46 (24.1)
3 105 (26.3) 68 (32.6) 37 (19.4)
4 (Highest) 79 (19.8) 59 (28.2) 20 (10.5)
Total social support score quartiles
1 (Lowest) 115 (28.8) 74 (35.4) 41 (21.5) 0.0039
2 103 (25.8) 56 (26.8) 47 (24.6)
3 104 (26.0) 48 (23.0) 56 (29.3)
4 (Highest) 78 (19.5) 31 (14.8) 47 (24.6)
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TABLE 3. Baseline Psychosocial Status in Relation to Change in Quality of Life Over 18 Months Follow-Up, Among HIV Infected
Adults Starting ART in Kampala, Uganda

Month 0
Diff (95% CI)
Month 6
Diff (95% CI)
Month 12
Diff (95% CI)
Month 18 Diff
(95% CI)
P-Value
Groupy
P-Value
T

Groupz
Stigma Adjusted
association
0.0150 0.8662
None 2.99 (0.48, 6.45) 1.65 (1.12, 4.42) 3.97 (0.43, 7.52) 3.76 (0.90, 6.62)
One 1.54 (2.35, 5.44) 0.54 (2.86, 3.94) 2.86 (1.17, 6.90) 2.70 (0.91, 6.30)
2þ Ref Ref Ref Ref
Depression Adjusted
association
<0.0001 <0.0001
Q1 (lowest) 14.15 (11.45, 16.84) 8.17 (5.75, 10.59) 6.46 (4.01, 8.92) 7.12 (4.41, 9.82)
Q2 9.31 (6.66, 11.97) 4.64 (1.82, 7.46) 3.27 (0.64, 5.89) 4.52 (1.90, 7.15)
Q3 5.67 (2.67, 8.68) 3.19 (0.42, 5.96) 2.19 (0.48, 4.86) 4.66 (1.85, 7.47)
Q4 (highest) Ref Ref Ref Ref
Anxiety Adjusted
association
<0.0001 <0.0001
Q1 (lowest) 12.57 (9.71, 15.42) 6.80 (4.15, 9.45) 6.14 (3.46, 8.82) 3.28 (1.01, 5.56)
Q2 8.16 (5.07, 11.24) 4.89 (2.06, 7.72) 4.35 (1.60, 7.10) 1.98 (0.48, 4.45)
Q3 5.29 (2.23, 8.34) 2.97 (0.03, 5.98) 3.14 (0.42, 5.85) 0.53 (3.15, 2.10)
Q4 (highest) Ref Ref Ref Ref
Social
support
Adjusted
association
0.0005 0.8943
Q1 (lowest) 4.98 (7.64, 2.33) 4.08 (6.89, 1.26) 2.36 (4.82, 0.11) 3.91 (6.50, 1.33)
Q2 3.31 (6.04, 0.58) 2.09 (4.97, 0.79) 1.47 (3.74, 0.81) 3.01 (5.47, 0.54)
Q3 2.14 (4.84, 0.56) 1.64 (4.41, 1.12) 0.87 (3.12, 1.44) 1.75 (4.37, 0.88)
Q4 (highest) Ref Ref Ref Ref
CI¼ confidence interval, HAART¼ highly active antiretroviral therapy, HIV¼ human immunodeficiency virus, Q¼ quartile, QOL¼ quality of life.
Adjusted for age, sex, presence of own income, education, and current alcohol use. Results are derived from repeated measures linear mixed
models implemented with SAS PROCMIXED to calculate differences and 95%CIs for QOL score at baseline and each follow-up period in relation to
quartiles of patient reported depression, stigma, anxiety, and social-support at enrollment.
y Significance for baseline difference in QOL in relation to specified psychosocial variable.
z Significance test is for baseline psychosocial variable associated difference in rate/direction of QOL gain during follow-up.
FIGURE 1. Mean quality of life score and percent high self-rated health scores at months 0, 6, 12, and 18 among adult human
immunodeficiency virus (HIV)-infected patients from Kampala, Uganda.
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high prevalence in Ugandan adults with HIV.27 Our data show
that patients reporting none versus 2 or more stigmatizing
experiences start treatment with relative advantage that persists
and is widened to significance bymonths 12 and 18. Thus, given
HAART, the rate of increase in QOL does not appear to vary by
level of reported stigma at beginning of therapy. However, the
stigma-related disadvantage in wellbeing at baseline is sus-
tained for as much as 18 months and may continue to contribute
to the disparity of patients’ subjective wellbeing.
Our finding that the overall trend in QOL change over 18
months was not significantly dependent on baseline level of
social support is inconsistent with prospective findings among
HIV infected men from the United States reported8 and with
findings from cross-sectional epidemiologic studies imple-
mented in United States, Canada, and Venezuela.28–32 Epide-
miologic studies among US veterans have shown that a greater
magnitude of the positive impacts of social support on QOL is
indirectly exerted by buffering the negative effects of adverse
psychosocial determinants such as depression and anxiety on
HRQOL.28,32 A greater perception of social support directly and
indirectly contribute to improved wellbeing by creating
environments that make recipients more likely to engage in
behavioral and psychological processes or physical activi-
ties33,34 that decrease psychosocial and physiologic stress35
with downstream salutatory impacts on overall QOL. Despite
a significant baseline social support dependent change in QOL
TABLE 4. Baseline Psychosocial Status and Likelihood of High Self-Rated Health

Over 18 Months Among Adult AIDS Patients
Starting ART in Kampala, Uganda
Month 0
OR (95% CI)
Month 6
OR (95% CI)
Month 12
OR (95% CI)
Month 18
OR (95% CI)
P-Value
Groupy
P-Value
T

Groupz
Stigma Adjusted association§ 0.7923 0.5126
None 1.30
(0.67, 2.52)
1.10
(0.54, 2.27)
1.13
(0.49, 2.59)
1.14
(0.48, 2.70)
One 0.96
(0.44, 2.08)
1.66
(0.68, 4.09)
0.99
(0.37, 2.61)
0.75
(0.28, 2.01)
2þ Ref Ref Ref Ref
Depression Adjusted association§ <0.0001 0.5837
Q1
(lowest)
4.89
(2.54, 9.42)
2.54
(1.15, 5.57)
2.29
(0.97, 5.42)
4.99
(2.02, 12.36)
Q2 1.92
(1.04, 3.54)
1.15
(0.60, 2.20)
1.37
(0.67, 2.81)
2.42
(1.18, 4.96)
Q3 1.18
(0.60, 2.32)
0.74
(0.37, 1.50)
1.17
(0.53, 2.56)
1.90
(0.90, 4.03)
Q4
(highest)
Ref Ref Ref Ref
Anxiety Adjusted Association§ 0.0022 0.7100
Q1
(lowest)
3.32
(1.77, 6.20)
1.75
(0.88, 3.47)
1.71
(0.79, 3.70)
3.47
(1.48, 8.11)
Q2 1.73
(0.91, 3.30)
1.59
(0.77, 3.29)
1.58
(0.70, 3.54)
1.77
(0.81, 3.87)
Q3 1.07
(0.56, 2.02)
1.00
(0.51, 1.96)
1.12
(0.53, 2.35)
1.49
(0.71, 3.12)
Q4
(highest)
Ref Ref Ref Ref
Social support Adjusted association§ 0.0037 0.6043
Q1
(lowest)
0.36
(0.19, 0.68)
0.49
(0.23, 1.05)
0.60
(0.25, 1.43)
0.23
(0.08, 0.63)
Q2 0.65
(0.34, 1.22)
0.57
(0.26, 1.24)
0.56
(0.24, 1.29)
0.35
(0.12, 0.98)
Q3 0.79
(0.42, 1.50)
0.78
(0.35, 1.72)
1.13
(0.45, 2.84)
0.42
(0.14, 1.22)
Q4
(highest)
Ref Ref Ref Ref
Results are derived from repeated measures generalized estimating equations models implemented with SAS PROC GENMOD to calculate ORs
and 95% confidence intervals for likelihood of high SRH at baseline and each follow-up period in relation to quartiles of patient reported depression,
stigma, anxiety, and social-support at enrollment. AIDS¼ acquired immune deficiency syndrome, CI¼ confidence interval, OR¼ odds ratio,
Q¼ quartile, SRH¼ self-rated health.
SRH is dichotomously defined in each interval as poor/fair versus good, very good, or excellent subjective health status in relation to healthy adult
of same age/sex in the patient’s community.
ySignificance for psychosocial variable.
zSignificance for psychosocial variable with time.
§ Adjusted for age, sex, presence of own income, education, and current alcohol use.
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over 18 months, our data show that the low social-support
associated disadvantage present at baseline persisted throughout
follow-up for least versus most supported quartiles and suggests
that enhancement of social support is likely to contribute to
enhancement of overall wellbeing among HIV-infected adults
on HAART.
Our study has limitations that must be considered in the
interpretation of our data. First psychosocial determinants were
only assessed at baseline; thus, significant associations between
stigma and QOLmay be a result of clinical status improvements
(i.e., HAART and social integration) overtime. Thus, the com-
plex relationship between stigma and QOL among PLH was
difficult to understand. Specifically, psychosocial determinants
were measured by patient report in the context of face-to-face
interview with study personnel. Therefore, differential recall of
experiences and/or social desirability bias leading to an over
reporting or underreporting of psychosocial and behavioral
attributes may have occurred.
The prospective nature of this investigation which allows
for temporal inference, our use of culturally adapted QOL
questionnaire with good psychometric properties for assessment
of wellbeing in HIV-positive adults, investigation within a
clinically well characterized large sample of HIV-infected
adults with up to 18 months of follow-up, and rigorous control
for important socio-demographic confounders are key strengths
this study. Of importance for the psychosocial measures and
outcomes under investigation, we eliminate the confounding
effect differential access to healthcare by restricting investi-
gation to patients already connected to care while analytically
controlling for baseline health indicators such as nutritional
status.
In summary, we report, a dose-dependent and sustained
QOL disadvantage over 18 months of follow-up in relation to
high depressive symptoms and anxiety in HIV-infected Ugan-
dan adults on HAART at baseline. Interventions such as cog-
nitive behavioral stress management have shown improvement
in QOL for African American women living with acquired
immune deficiency syndrome36 and have reduced various
mental health disorders (anxiety, depression, distress, and fati-
gue), while improving QOL in white male HIV patients.37 Thus,
in an era of long-term survival with chronic HIV, interventions
that combine stress management and psychosocial support
programs within clinical practice are likely to enhance overall
well-being of patients on HAART.
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